This is a working overview of peptide research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-28 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
=== Twitter defamation case === In April 2022, Galloway's Twitter account was labelled "Russian state-affiliated media" by Twitter. In response Galloway tweeted: "I work for NO Russian media. I have 400,000 followers. I'm the leader of a British political party and spent nearly 30 years in the British parliament. If you do not remove this designation I will take legal action." Twitter users pointed out that Galloway's profile named the Russian state media outlets that he worked for. Galloway then removed these from his profile. He said Twitter had refused to explain the label, which he said was added to his account after he had stopped presenting on Russian television channels, which were closed by the British government in March 2022. Galloway sued Twitter for defamation in the High Court, Dublin. The suit also alleged that Twitter had unlawfully processed his personal data by labelling and censoring his account. In October 2024, the High Court in Dublin ordered Twitter to pay Galloway's legal costs. It also ordered both parties to "submit sworn affidavits attesting to the truth of their claims" by 30 January 2025.
In 2018, El Salvador cut diplomatic ties with Taiwan and recognized the People's Republic of China as China's legitimate government. This led to Bukele and the United States accusing China of interfering in Salvadoran and Latin American politics. Despite Bukele's criticism of China before becoming president, Vice President Félix Ulloa stated in May 2019 that Bukele's government would not restore diplomatic relations with Taiwan. In December 2019, Bukele met Chinese leader Xi Jinping in Beijing and signed a "gigantic" infrastructure agreement with China for an unknown amount of money. El Salvador and China have cooperated on infrastructure projects in El Salvador such as the National Library of El Salvador (completed in November 2023) and the National Stadium of El Salvador (construction began in November 2023). In November 2022, Bukele announced that El Salvador and China had begun negotiations for a free trade agreement between the countries. China donated fertilizer and wheat flour to El Salvador and, according to a Salvadoran government official, offered to buy El Salvador's external bond debt. Bukele stated that a free trade agreement with China was "very important" because El Salvador had been "isolated from [the] potential" of China's economic strength.
Breen attacks Gordon by firing at him with the supercharged Gravity Gun; however, the charge does not kill him, and Breen leaves it behind while escaping. Gordon manages to stop him by destroying the Citadel's dark fusion reactor, which destroys the teleporter Breen attempted to use to escape in a massive explosion; the platform Breen was standing on collapses, dropping Breen from the Citadel to his death.
== Receptor action == GnIH binds to the Gαi protein coupled receptor GPR147 to suppress adenylyl cyclase formation of cAMP and inhibit protein kinase cascades affecting gene expression. GnIH inhibits the same signaling pathway that GnRH activates to promote follicle stimulating hormone (FSH) and luteinizing hormone (LH) expression. The compound RF9 is a known GPR147 receptor antagonist.
Arguing in favour of independence, President Mangope claimed that the move would enable its population to negotiate with Pretoria from a stronger position: "We would rather face the difficulties of administering a fragmented territory, the wrath of the outside world, and accusations of ill-informed people. It's the price we are prepared to pay for being masters of our own destiny." United Nations Secretary-General Kurt Waldheim stated that he "strongly deplored" the establishment of "another so-called independent tribal homeland in pursuance of the discredited policies of apartheid", and in resolution A/RES/32/105N, passed on 14 December 1977, the United Nations General Assembly linked Bophuthatswana's "so-called 'independence'" to South Africa's "stubborn pursuit" of its policies, and called upon all governments to "deny any form of recognition to the so-called 'independent' bantustans". During a parliamentary debate in the UK on 6 December 1977, Foreign Secretary David Owen replied in the negative when asked "whether Her Majesty's Government intend to recognise travel documents issued by the authorities of ... Bophuthatswana for the purpose of admitting visitors to the United Kingdom". While the majority of news reports echoed these official declarations, there were others which opined that Western critics should "suspend judgment for a time", and despite its generally critical stance on South Africa's policies, Time magazine wrote that Bophuthatswana had "considerable economic potential" with an expected $30 million a year coming from mining revenues.
Sources: en.wikipedia.org
During the show's ninth season, which has subsequently been entirely retconned out of the series continuity, Bev comes out as a lesbian (according to one of Roseanne's fictional twists on her family, along with winning the lottery). In the finale, Roseanne states that it is her sister, Jackie, not Bev, who is a lesbian. This has also been retconned out of the series continuity. From what is known of Bev's childhood and marriage, her life was emotionally difficult, plagued with instability and neglect. Her unrestrained mother Mary put her personal freedom ahead of her children. As a result of her promiscuity, Mary is uncertain about who Bev's father was. As a young woman, Bev found herself pregnant out of wedlock, as her mother had been. Unlike her mother, Bev married her baby's father, Al Harris. Their marriage lasted several decades, but Al treated their two daughters harshly and cheated on Bev, having a secret mistress for twenty years. Disappointed in her life, Bev grew bitter in her old age, making her critical of others. Bev returned in season 10 of Rosanne, and in the subsequent follow-up series The Conners. In season 10 of Roseanne, Bev was kicked out of her retirement community for sleeping with others and spreading STIs; Jackie and Roseanne alternated keeping care of her at their respective homes.
== Research == Biggar's research includes many different areas from different fields within molecular biology, biochemistry, and physical biochemistry. His main areas of research interest are Oxidative Cell Stress, Functional Proteomics, Bioinformatics, and Molecular Pharmacology. He is particularly known for his research in the new field of Non-histone Lysine Methylation and its relation to both functional proteomics and cell stress.
== Tolerance and overdoses == Fatal opioid overdose typically occurs due to bradypnea, hypoxemia, and decreased cardiac output (hypotension occurs due to vasodilation, and bradycardia further contributes to decreased cardiac output). A potentiation effect occurs when opioids are combined with ethanol, benzodiazepines, barbiturates, or other central depressants which can result in rapid loss of consciousness and an increased risk of fatal overdose. Substantial tolerance to respiratory depression develops quickly, and tolerant individuals can withstand larger doses. However, tolerance to respiratory depression is quickly lost during withdrawal and may be completely reversed within a week. Many overdoses occur in people who return to their previous dose after having lost their tolerance following cessation of opioids. This puts addicts who receive medical treatment for opioid addiction at great risk of overdose when they are released, as they may be particularly vulnerable to relapse. Less commonly, massive overdoses have been known to cause circulatory collapse from vasodilation and bradycardia. Opioid overdoses can be rapidly reversed through the use of opioid antagonists, naloxone being the most widely used example. Opioid antagonists work by binding competitively to μ-opioid receptors and displacing opioid agonists. Additional doses of naloxone may be necessary and supportive care should be given to prevent hypoxic brain injury by monitoring vital signs.
DNA binding site prediction on protein DNA the Double Helix Game From the official Nobel Prize web site DNA under electron microscope Dolan DNA Learning Center Double Helix: 50 years of DNA, Nature Proteopedia DNA Proteopedia Forms_of_DNA ENCODE threads explorer ENCODE home page at Nature Double Helix 1953–2003 National Centre for Biotechnology Education Genetic Education Modules for Teachers – DNA from the Beginning Study Guide PDB Molecule of the Month DNA "Clue to chemistry of heredity found". The New York Times, June 1953. First American newspaper coverage of the discovery of the DNA structure DNA from the Beginning Another DNA Learning Center site on DNA, genes, and heredity from Mendel to the human genome project. The Register of Francis Crick Personal Papers 1938 – 2007 at Mandeville Special Collections Library, University of California, San Diego Seven-page, handwritten letter that Crick sent to his 12-year-old son Michael in 1953 describing the structure of DNA. See Crick's medal goes under the hammer, Nature, 5 April 2013.
In 2015, the Department of Defense released an updated cyber strategy memorandum detailing the present and future tactics deployed in the service of defense against cyberwarfare. In this memorandum, three cybermissions are laid out. The first cybermission seeks to arm and maintain existing capabilities in the area of cyberspace, the second cybermission focuses on prevention of cyberwarfare, and the third cybermission includes strategies for retaliation and preemption (as distinguished from prevention). One of the hardest issues in cyber counterintelligence is the problem of cyber attribution. Unlike conventional warfare, figuring out who is behind an attack can be very difficult.
Sources: en.wikipedia.org
Sample warming can be controlled by bead beating for short time intervals with cooling on ice between each interval, by processing vials in pre-chilled aluminum vial holders or by circulating gaseous coolant through the machine during bead beating. A different bead beater configuration, suitable for larger sample volumes, uses a rotating fluorocarbon rotor inside a 15, 50 or 200 ml chamber to agitate the beads. In this configuration, the chamber can be surrounded by a static cooling jacket. Using this same rotor/chamber configuration, large commercial machines are available to process many liters of cell suspension. Currently, these machines are limited to processing unicellular organisms such as yeast, algae and bacteria.
Hirsutism is excessive body hair on parts of the body where hair is normally absent or minimal. The word is from the early 17th century: from Latin hirsutus meaning "hairy". It usually refers to a male pattern of hair growth in a female that may be a sign of a more serious medical condition, especially if it develops well after puberty. Cultural stigma against hirsutism can cause much psychological distress and social difficulty. Discrimination based on facial hirsutism often leads to the avoidance of social situations and to symptoms of anxiety and depression. Hirsutism is usually the result of an underlying endocrine imbalance, which may be adrenal, ovarian, or central. It can be caused by increased levels of androgen hormones. The amount and location of the hair is measured by a Ferriman–Gallwey score. It is different from hypertrichosis, which is excessive hair growth anywhere on the body. Treatments may include certain birth control pills, antiandrogens, or insulin sensitizers. Hirsutism affects between 5 and 15% of women across all ethnic backgrounds. Depending on the definition and the underlying data, approximately 40% of women have some degree of facial hair. About 10 to 15% of cases of hirsutism are idiopathic with no known cause.
=== Hylomorphism in contemporary anthropology === Anthropologist Tim Ingold has critiqued the classical hylomorphic model in his article The Textility of Making (2010), arguing that form is not imposed on passive matter by an external agent but instead "emerges within the process of making". He describes this alternative as a morphogenetic approach, influenced by process philosophy and drawing on ideas from Gilles Deleuze and Félix Guattari. Ingold emphasizes the active participation of materials, proposing that making is a relational and temporal unfolding rather than the execution of a predefined design.
A cofactor is a non-protein chemical compound or metallic ion that is required for an enzyme's role as a catalyst. Cofactors can be considered "helper molecules" that assist in biochemical transformations. The rates at which these happen are characterized in an area of study called enzyme kinetics. Cofactors typically differ from ligands in that they often derive their function by remaining bound. Cofactors can be classified into two types: inorganic ions and complex organic molecules called coenzymes. Coenzymes are mainly derived from vitamins and other organic essential nutrients in small amounts (some definitions limit the use of the term "cofactor" for inorganic substances; both types are included here). Coenzymes are further divided into two types. The first is called a "prosthetic group", which consists of a coenzyme that is tightly (or even covalently and, therefore, permanently) bound to a protein. The second type of coenzymes are called "cosubstrates", and are transiently bound to the protein. Cosubstrates may be released from a protein at some point, and then rebind later. Both prosthetic groups and cosubstrates have the same function, which is to facilitate the reaction of enzymes and proteins. An inactive enzyme without the cofactor is called an apoenzyme, while the complete enzyme with cofactor is called a holoenzyme.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.